News >

EU Panel Recommends Revoking Olaratumab in Soft Tissue Sarcoma

Gina Columbus @ginacolumbusonc
Published: Monday, Apr 29, 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the conditional marketing authorization for olaratumab (Lartruvo) be revoked following results of the ANNOUNCE study, which did not demonstrate a survival benefit with the PDGFRα antagonist in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma (STS).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication